Which companies are KPC Pharmaceuticals's closest peers?

The cockpit's peer set: Harbin Gloria Pharmaceuticals (002437.SZ), Harrow (HROW), Savara (SVRA), SSY (2005.HK), Oscotec (039200.KS), Zhejiang Garden Biopharmaceutical (300401.SZ), MoonLake Immunotherapeutics (MLTX), Guangxi Wuzhou Zhongheng (600252.SS).

Is KPC Pharmaceuticals expensive compared with its peers?

On ev / sales it trades at 1.9× against a peer median of 2.3×, 8th cheapest of 18 in its peer set.

How has KPC Pharmaceuticals stock performed?

Over six months to 6 Nov 2026 the shares returned -6.7% against -12.8% for the median peer; over one year -37.2%.

← CockpitCompetitor Analysis › 600422.SS KPC Pharmaceuticals, Inc. Class AOpen in the cockpit ↗

KPC Pharmaceuticals, Inc. Class A600422.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Momentum leader 81

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$1.00B

US dollars, full cap

Free float

62%

of shares outstanding

$/day

$12.8M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-8.0 pp

WACC 5.0%

Hurdle

n/a

no reverse DCF

Next earnings

133 days

19 Mar 2027

Close · CNYCN¥8.86

1D0.0%

1W+2.2%

1M+8.3%

3M-3.4%

6M-6.7%

YTD-29.5%

1Y-37.2%

ATR %2.8%

52w lowhigh37.3% off high

What KPC Pharmaceuticals does

Employees: 5,072

KPC Pharmaceuticals at a glance

Size KPC Pharmaceuticals (600422.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.00B, the 2293rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.86 on 6 Nov 2026.

Performance Over six months the shares fell 6.7%, against -12.8% for the median peer and -16.4% for the China market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue fell 40.8% over the last twelve months (peer median +6.8%); the operating margin is -10.5% (peer median 8.7%).

Valuation It trades at 1.9× enterprise value to sales against a peer median of 2.3× (8th cheapest of 18).

Capital Return on invested capital runs 8.0 points below its cost of capital (5.0% WACC).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: KPC Pharmaceuticals against the median of its 20 peers (local-currency closes).

KPC Pharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥4.55B	CN¥6.54B	CN¥8.34B	CN¥8.37B	CN¥8.23B
Revenue growth	—	-22%	0%	+2%	—
Gross profit	CN¥1.31B	CN¥2.38B	CN¥3.48B	CN¥3.77B	CN¥3.26B
EBITDA	n/a	CN¥442M	CN¥1.01B	CN¥900M	CN¥675M
Net income	-CN¥285M	CN¥350M	CN¥648M	CN¥541M	CN¥383M
Free cash flow	-CN¥676M	CN¥229M	CN¥744M	CN¥660M	CN¥161M
Capital expenditure	CN¥126M	CN¥90.6M	CN¥79.4M	CN¥110M	CN¥102M
Total debt	CN¥1.82B	CN¥2.11B	CN¥1.45B	CN¥1.21B	CN¥1.43B

Quarterly statements and history in the cockpit →

KPC Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. KPC Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. KPC Pharmaceuticals is the large dot.

KPC Pharmaceuticals competitors and peer comparison

How KPC Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

KPC Pharmaceuticals against its 20 peers (data as of 6 Nov 2026)
Measure	600422.SS	Peer median	Rank in peer set
1-month return	+8.3%	-2.9%	3rd highest of 21
6-month return	-6.7%	-12.8%	5th highest of 20
Distance from 52-week high	-37.3%	-28.3%	8th lowest of 21
Revenue growth (TTM)	-40.8%	+6.8%	3rd lowest of 18
Operating margin	-10.5%	8.7%	4th lowest of 18
EV / Sales	1.9×	2.3×	8th cheapest of 18
ROIC minus cost of capital	-8.0 pp	-0.7 pp	4th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
KPC Pharmaceuticals 600422.SS	China	$1.00B	-7%	-41%	-10%	1.9×	n/a	n/a
Harbin Gloria Pharmaceuticals 002437.SZ	China	$999M	-15%	-16%	13%	3.0×	8.8%	-6.9%
Harrow HROW	United States	$1.01B	-30%	+21%	2%	4.4×	51.8%	+41.0%
Savara SVRA	United States	$992M	-8%	n/a	n/a	n/a	n/a	n/a
SSY 2005.HK	Hong Kong	$990M	+10%	-4%	12%	2.3×	2.1%	-0.5%
Oscotec 039200.KS	South Korea	$1.02B	-30%	+233%	62%	8.3×	-9.5%	+18.1%
Zhejiang Garden Biopharmaceutical 300401.SZ	China	$983M	-7%	+2%	24%	5.5×	10.2%	+13.4%
MoonLake Immunotherapeutics MLTX	United States	$981M	-32%	n/a	n/a	n/a	n/a	n/a
Guangxi Wuzhou Zhongheng 600252.SS	China	$1.03B	-11%	-43%	-42%	5.0×	11.9%	-13.7%
Symbiotec Pharmalab SYMBIOTEC.NS	India	$1.03B	n/a	n/a	n/a	n/a	n/a	n/a
SAWAI 4887.T	Japan	$1.03B	-22%	+11%	9%	1.3×	n/a	n/a
Towa Pharmaceutical 4553.T	Japan	$1.03B	-16%	+7%	9%	1.2×	1.5%	+12.1%
Jiangsu Yahong Meditech 688176.SS	China	$973M	-12%	+15%	-172%	17.8×	n/a	n/a
Strides Pharma Science STAR.NS	India	$973M	-13%	+11%	14%	2.1×	18.1%	+7.8%
Kissei Pharmaceutical 4547.T	Japan	$973M	-16%	+6%	6%	1.1×	n/a	n/a
Procter & Gamble Health PGHL.NS	India	$971M	+4%	+13%	31%	6.3×	5.5%	+9.3%
Sunflower Pharmaceutical 002737.SZ	China	$1.04B	-13%	+31%	-7%	1.8×	-6.4%	-7.7%
Jiangsu Kanion Pharmaceutical 600557.SS	China	$1.05B	-6%	+8%	7%	1.5×	3.4%	+1.8%
Immatics IMTX	United States	$952M	-44%	-65%	-556%	10.7×	n/a	n/a
Renhe Pharmacy 000650.SZ	China	$1.06B	-10%	-7%	14%	1.0×	-9.4%	-7.0%
Northeast Pharmaceutical 000597.SZ	China	$948M	-10%	-6%	3%	1.0×	-6.8%	-0.7%

Questions

Which companies are KPC Pharmaceuticals's closest peers?: The cockpit's peer set: Harbin Gloria Pharmaceuticals (002437.SZ), Harrow (HROW), Savara (SVRA), SSY (2005.HK), Oscotec (039200.KS), Zhejiang Garden Biopharmaceutical (300401.SZ), MoonLake Immunotherapeutics (MLTX), Guangxi Wuzhou Zhongheng (600252.SS).
Is KPC Pharmaceuticals expensive compared with its peers?: On ev / sales it trades at 1.9× against a peer median of 2.3×, 8th cheapest of 18 in its peer set.
How has KPC Pharmaceuticals stock performed?: Over six months to 6 Nov 2026 the shares returned -6.7% against -12.8% for the median peer; over one year -37.2%.